Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 1.00 |
| ▸ | ABL1 | P00519 | 7/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CSK | P41240 | 2/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 2/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 1/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.64 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.64 |
| ▸ | AKT1 | P31749 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387799 | 1.00 | SRC (1.00) | SRCABL1PRKD3PRKD1PRKD2 | |
| SCHEMBL29390287 | 1.00 | SRC (1.00) | SRCABL1PRKD3PRKD1PRKD2 | |
| SCHEMBL13063869 | 0.87 | SRC (0.77) | SRCABL1PRKD3PRKD1PRKD2 | |
| SCHEMBL13063867 | 0.87 | SRC (0.77) | SRCABL1PRKD3PRKD1PRKD2 | |
| SCHEMBL13019708 | 0.85 | SRC (0.74) | SRCABL1PRKD3PRKD1PRKD2 | |
| SCHEMBL12551799 | 0.85 | SRC (0.73) | SRCABL1PRKD3PRKD1PRKD2 | |
| SCHEMBL1961871 | 0.85 | SRC (0.73) | SRCABL1PRKD3PRKD1PRKD2 | |
| SCHEMBL14574647 | 0.85 | SRC (0.73) | SRCABL1PRKD3PRKD1PRKD2 | |
| SCHEMBL29387839 | 0.85 | SRC (0.73) | SRCABL1PRKD3PRKD1PRKD2 | |
| SCHEMBL13019738 | 0.84 | SRC (0.73) | SRCABL1PRKD3PRKD1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913932-B2 | Maturation of mammalian hepatocytes | TAKARA BIO EUROPE AB (SE) | 2021-02-09 | — | — | US | claimed |
| WO-2020242910-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OFCALIFORNIA (US) | 2020-12-03 | — | — | WO | claimed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | claimed |
| EP-2528919-B1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIV WASHINGTON (US) | 2016-11-02 | — | — | EP | claimed |
| EP-1196626-B1 | METHODS FOR IDENTIFYING INHIBITORS OF SIGNALING MOLECULES | UNIV PRINCETON (US) | 2006-05-10 | — | — | EP | claimed |
| US-6610483-B1 | Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof | PRINCETON UNIVERSITY | 2003-08-26 | — | — | US | claimed |
| US-20250297310-A1 | HEMATOPOIETIC LOSS OF Y CHROMOSOME LEADS TO CARDIAC FIBROSIS AND DYSFUNCTION AND IS ASSOCIATED WITH DEATH DUE TO HEART FAILURE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4416306-A1 | METHODS FOR DETERMINING THE LIKELIHOOD OF A MALIGNANT DISEASE RESPONDING TO TREATMENT WITH A PHARMACEUTICAL INHIBITOR | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2024-08-21 | — | — | EP | disclosed |
| EP-3700516-B1 | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION | SONIC MASTER LTD (VG) | 2024-01-24 | — | — | EP | disclosed |
| US-20240016840-A1 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | JUNO THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023183822-A1 | HEMATOPOIETIC LOSS OF Y CHROMOSOME LEADS TO CARDIAC FIBROSIS AND DYSFUNCTION AND IS ASSOCIATED WITH DEATH DUE TO HEART FAILURE | UNIVERSITY OF VIRGINA PATENT FOUNDATION (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| EP-1321467-A2 | High affinity inhibitors for target validation and uses thereof | Princeton University (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | PRINCETON UNIVERSITY | 2003-04-17 | — | — | US | disclosed |
| US-6383790-B1 | PYRAZOLO(3,4-D)PYRIMIDINE BASED COMPOUND; ANTICARCINOGENIC AGENTS; ANTITUMOR AGENTS | PRINCETON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| EP-1196626-A2 | METHODS FOR IDENTIFYING INHIBITORS OF SIGNALING MOLECULES | Princeton University (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1140938-A2 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | Princeton University (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001007659-A2 | METHODS FOR IDENTIFYING INHIBITORS OF SIGNALING MOLECULES | PRINCETON UNIVERSITY (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000042042-A2 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | PRINCETON UNIVERSITY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | SRC 4695/4885ABL1 553/4885PRKD3 4033/4885 |
| US-20240016840-A1 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | ITK, PBK, BMX | SRC 32/4885ABL1 39/4885PRKD3 876/4885 |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885PRKD3 58/4885 |
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | SRC, MARCKS, TEC | SRC 1/4885ABL1 18/4885PRKD3 323/4885 |
| US-20250297310-A1 | HEMATOPOIETIC LOSS OF Y CHROMOSOME LEADS TO CARDIAC FIBROSIS AND DYSFUNCTION AND IS ASSOCIATED WITH DEATH DUE TO HEART FAILURE | YWHAG, MYLK2, TERF2 | SRC 699/4885ABL1 1871/4885PRKD3 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.